Tumour cells, with stem-like properties, are highly aggressive and often show drug resistance. Here, we reveal that integrin α v β 3 serves as a marker of breast, lung and pancreatic carcinomas with stem-like properties that are highly resistant to receptor tyrosine kinase inhibitors such as erlotinib. This was observed in vitro and in mice bearing patient-derived tumour xenografts or in clinical specimens from lung cancer patients who had progressed on erlotinib. Mechanistically, α v β 3 , in the unliganded state, recruits KRAS and RalB to the tumour cell plasma membrane, leading to the activation of TBK1 and NF-κB. In fact, α v β 3 expression and the resulting KRAS-RalB-NF-κB pathway were both necessary and sufficient for tumour initiation, anchorage independence, self-renewal and erlotinib resistance. Pharmacological targeting of this pathway with bortezomib reversed both tumour stemness and erlotinib resistance. These findings not only identify α v β 3 as a marker/driver of carcinoma stemness but also reveal a therapeutic strategy to sensitize such tumours to RTK inhibition.
1,6
Tumour cells, with stem-like properties, are highly aggressive and often show drug resistance. Here, we reveal that integrin α v β 3 serves as a marker of breast, lung and pancreatic carcinomas with stem-like properties that are highly resistant to receptor tyrosine kinase inhibitors such as erlotinib. This was observed in vitro and in mice bearing patient-derived tumour xenografts or in clinical specimens from lung cancer patients who had progressed on erlotinib. Mechanistically, α v β 3 , in the unliganded state, recruits KRAS and RalB to the tumour cell plasma membrane, leading to the activation of TBK1 and NF-κB. In fact, α v β 3 expression and the resulting KRAS-RalB-NF-κB pathway were both necessary and sufficient for tumour initiation, anchorage independence, self-renewal and erlotinib resistance. Pharmacological targeting of this pathway with bortezomib reversed both tumour stemness and erlotinib resistance. These findings not only identify α v β 3 as a marker/driver of carcinoma stemness but also reveal a therapeutic strategy to sensitize such tumours to RTK inhibition.
Despite extensive efforts invested in the clinical development of cancer therapies, current treatments can control tumour growth initially but have produced only modest long term efficacy, because most of the patients ultimately relapse. Accumulating evidence implicates tumour-initiating cells (TICs), also known as cancer stem cells or tumour-propagating cells, as contributors to tumour dormancy, metastasis and relapse 1, 2 . TICs represent a subpopulation of highly tumorigenic cancer cells that are capable of anchorage independence, self-renewal and multilineage differentiation, properties that render these cells particularly resistant to therapy 3, 4 . Developing effective strategies to identify and target TICs will require a better understanding of the molecular mechanisms that drive TIC function. Although a number of cell surface proteins and adhesion molecules have already been identified as TIC markers for certain tumour types or subtypes 5, 6 , none have emerged as viable therapeutic targets to reverse tumour progression and drug resistance.
Integrin α v β 3 is a cell surface adhesion molecule that has been well established as a driver of tumour progression 7, 8 . Not only has expression of α v β 3 been associated with poor outcome and higher incidence of metastasis for a variety of epithelial cancers 8 , but its expression has also been reported on a subpopulation of breast [9] [10] [11] and leukaemia cancer stem cells 12 .
Although the primary function of integrins is thought to be coordination of cell-matrix communication to influence intracellular signalling cascades 8 , α v β 3 integrin is capable of triggering anchorage-independent cell survival and tumour metastasis in the absence of ligand binding 13 . Considering the presence of α v β 3 on some TIC populations and its role in permitting anchorage-independent survival, we reasoned that α v β 3 expression might be a marker of and functional contributor to a tumour stemness program that enables tumour cells to survive the environmental changes encountered during invasion, metastasis and exposure to cancer therapies.
We report here that α v β 3 is specifically upregulated on the surface of various epithelial tumour cells exposed to receptor tyrosine kinase (RTK) inhibitors, and α v β 3 expression is associated with enhanced tumour progression and drug resistance when compared with tumours lacking α v β 3 . In fact, we found that α v β 3 is both necessary and sufficient to reprogram breast, lung and pancreatic tumour cells towards a stem-like phenotype with specific resistance to RTK inhibitors. Mechanistically, α v β 3 expressed on the surface of tumour cells initiates a membrane-proximal complex with the Kirsten rat sarcoma viral oncogene homologue GTPase (KRAS) and the v-ral simian leukaemia oncogene homologue B GTPase (RalB) to activate the IKK-related kinase TBK1 and nuclear factor κB (NF-κB) and enhance anchorage independence, self-renewal, tumour initiation and RTK inhibitor resistance. Targeting this pathway genetically or pharmacologically not only reverses these stem-like properties but also resensitizes such tumours to RTK inhibition.
RESULTS
Integrin β 3 expression drives a tumour-initiating cell phenotype and RTK inhibitor resistance On a wide range of histologically distinct tumours, integrin α v β 3 expression has been linked to increased metastasis [13] [14] [15] [16] [17] . To assess a potential role for α v β 3 in tumour initiation using clinical samples, patient-derived lung and pancreatic xenografts were sorted into β 3 + and β 3 − subpopulations, transplanted into NOD/SCID Il2rγ −/− (NSG) recipient mice by limiting dilution and assessed for TICs. The β 3 + subpopulation from both tumour types was highly enriched (60-fold) in TICs relative to the β 3 − population ( Fig. 1a and Supplementary Fig. 1a,b) . In fact β 3 + but not β 3 − cells were able to form compact tumour spheres ( Fig. 1b and Supplementary Fig. 1c ). Also, β 3 + tumours contained both β 3 + and β 3 − cells, indicating that these cells can recapitulate the heterogeneity of the parental tumour (Fig. 1c) . We next assessed whether α v β 3 expression on a panel of carcinoma cell lines can impact properties commonly associated with tumour stem-like cells by both loss and gain of function studies. Compared with their respective β 3 − counterparts, β 3 + lung or pancreas tumours showed a 50-fold higher frequency of TICs when implanted into NSG or nude mice (Fig. 1d,e and Supplementary Fig. 1d-f ). These findings were corroborated in vitro among breast, lung and pancreatic cell lines, because β 3 + cells showed sixfold increased self-renewal properties (secondary tumour spheres) relative to β 3 − cells (Fig. 1f,g and Supplementary Fig. 1g ).
TICs are known to be particularly resistant to cellular stresses, such as nutrient deprivation or exposure to anti-cancer drugs 3 . Indeed, β 3 + cells showed a fourfold survival advantage, compared with their β 3 − counterparts, when subjected to nutrient deprivation (Fig. 2a) . Accordingly, we noted that β 3 expression conferred resistance to RTK inhibitors such as the epidermal growth factor receptor (EGFR) inhibitors erlotinib and lapatinib, as well as the insulin-like growth factor 1 receptor inhibitor linsitinib, yet these cells remained sensitive to chemotherapeutic agents such as gemcitabine and cisplatin ( Fig. 2b-d and Supplementary Fig. 2a-c) . Whereas previous studies have linked tumour stemness to a general drug resistance phenotype 3, 4 , our findings reveal a stem-like tumour cell population that seems to be selectively resistant to RTK inhibitors. Importantly, this link between α v β 3 expression and RTK inhibitor resistance was also observed in vivo, as knockdown of integrin β 3 sensitized A549 human lung carcinoma xenografts to erlotinib, whereas ectopic expression of integrin β 3 conferred erlotinib resistance to fast-growing (FG) human pancreatic carcinoma tumours growing orthotopically in the pancreas (Fig. 2e,f and Supplementary Fig. 2d ). We next evaluated a broad panel of breast, pancreas and lung cancer cell lines for their endogenous expression of α v β 3 and assessed their intrinsic sensitivity to erlotinib. All α v β 3 -expressing cells tested showed an increased intrinsic resistance to erlotinib (ranging from 3-to 60-fold) relative to tumours not expressing this receptor independently of EGFR or KRAS mutational status ( Supplementary Fig. 2e ). Together, these findings indicate that α v β 3 expression is both necessary and sufficient to induce tumour cell stem-like properties, including resistance to RTK inhibition.
Integrin-mediated adhesion/ligation is known to promote tumour cell survival and progression 8 . Therefore we considered whether inhibiting the ligand-binding properties of α v β 3 could reverse tumour stemness and/or sensitize tumours to RTK inhibitors. Interestingly, integrin antagonists that compete for ligand binding and disrupt cell adhesion had no effect on the ability of α v β 3 to induce tumour cell stemness or resistance to RTK inhibitors ( Supplementary Fig. 2f ). Furthermore, tumour cells expressing a mutant integrin β 3 (D119A) incapable of binding ligand 13 showed erlotinib resistance to the same degree as cells expressing wild-type β 3 ( Supplementary Fig. 2g) . Thus, the contribution of α v β 3 to tumour cell stemness and RTK inhibitor resistance seems to involve a non-canonical function for this integrin, independent from its traditional role as a mediator of cell adhesion. Together, these findings indicate that the presence of α v β 3 on histologically distinct carcinomas induces a stem-like, drug-resistant phenotype that is independent of its capacity to induce adhesionmediated signalling.
Acquired resistance to EGFR inhibition selects for a β 3 + cell population with TIC properties
Patients with non-small cell lung cancer (NSCLC) often respond to erlotinib but invariably develop resistance through multiple mechanisms (including EGFR mutations, EGFR gene amplification and alternative routes of kinase pathway activation [18] [19] [20] [21] ). However, accumulating evidence supports the concept that outgrowth of TICs contributes to this process 22, 23 . To explore a possible role for α v β 3 in acquired resistance we examined a lung carcinoma cell line (HCC827 cells) that harbours a clinically relevant deletion of exon 19 of EGFR but that lacks α v β 3 expression. Tumour-bearing mice were systemically treated with erlotinib for 90 days until resistance emerged and monitored for the induction of α v β 3 (Fig. 3a) . Once erlotinib resistance was observed, tumours expressed a qualitative increase in α v β 3 relative to tumours in vehicle-treated mice ( Fig. 3b and Supplementary Fig. 3a) . Accordingly, α v β 3 expression was also qualitatively increased on two other orthotopic cancer models (H441, lung cancer, and FG, pancreas cancer) after sustained erlotinib treatment (Fig. 3c,d and Supplementary Fig. 3b,c) . Thus, systemic erlotinib treatment of mice bearing human lung and pancreas cancers drives α v β 3 expression, which coincides with the acquisition of drug resistance.
To assess a possible role for α v β 3 expression as a primary mediator of tumour stemness, we prepared single-cell suspensions from erlotinib-resistant HCC827 tumours, sorted these cells into integrin β 3 + and β 3 − populations and assessed their tumour-initiating abilities in mice and their stem-like properties in vitro. The β 3 + sorted population showed enhanced self-renewal capacities (fourfold) and tumour initiation (100-fold) relative to the β 3 − population (Fig. 3e,f and Supplementary Fig. 3d ,e), and completely accounted for the stemlike properties among the drug-resistant population. Supporting this notion, the β 3 + population was able to reconstitute the heterogeneity Supplementary  Fig. 1f . (f) Self-renewal capacity of A549, PANC-1 and MDA-MB-231 Lm2 cells expressing control or β 3 shRNA measured by quantifying the number of primary and secondary tumour spheres. The bar graph represents the mean ± s.d. for n = 3 independent experiments for PANC-1 and A549 cells and the mean for a representative experiment with three wells per group for MDA-MB-231 Lm2; the experiment was repeated twice. (g) Self-renewal capacity of FG cells expressing control vector or integrin β 3 , measured by quantifying the number of primary and secondary tumour spheres. The bar graph represents the mean ± s.d. for n = 3 independent experiments. The P-value was estimated by Student's t-test in b,f,g and χ 2 test in a,d,e. *P < 0.05, **P < 0.01, ***P < 0.001. Original data for b,f,g are provided in the statistical source data (Supplementary Table 3 ).
of the primary tumour revealing the presence of both β 3 + and β 3 − cells (Fig. 3g) . Furthermore, these erlotinib-resistant lung tumours (HCC827) showed a 16-fold increase in the stem marker ALDH1
( Supplementary Fig. 3f ), whereas knockdown of endogenous β 3 in A549 lung carcinoma cells resulted in a significant decrease in ALDH1 expression (Supplementary Fig. 3g ). These findings were Table 3 ).
validated in patient biopsies, as integrin β 3 gene (ITGB3) expression was significantly upregulated on a cohort of lung cancer patients in the BATTLE trial 24 who had progressed on erlotinib relative to patients who had not been treated with this drug (Fig. 3h) . Moreover, α v β 3 expression as detected by immunostaining was not expressed on primary lung tumour biopsies before treatment but was highly upregulated on these same primary tumours after progression on erlotinib (Fig. 3i) . Together, these findings reveal that erlotinibresistant tumours show enriched α v β 3 expression, which seems to be necessary and sufficient to account for both tumour stemness and erlotinib resistance.
Integrin-β 3 -KRAS complex is critical for a tumour-initiating phenotype and EGFR inhibitor resistance
Mechanistically, integrins are known to transmit signals in the context of one or more RAS family members 25 . Thus, we analysed tumour cells growing in three dimensions (3D) for a possible co-localization between α v β 3 and one or more RAS family members. Integrin α v β 3 co-localized specifically with KRAS in membrane clusters and was not co-localized with NRAS, RRAS or HRAS in these cells (Fig. 4a,b and Supplementary Fig. 4a-c) . Accordingly, KRAS could be specifically co-immunoprecipitated with α v β 3 but not with β 1 integrins (Fig. 4c) . Importantly, we observed that KRAS knockdown abolished α v β 3 -mediated anchorage independence, nutrient deprivation and erlotinib resistance as well as self-renewal, but did not impact these properties in cells lacking α v β 3 ( Fig. 4d-g and Supplementary Fig. 4d-f ), indicating that β 3 and KRAS probably cooperate to drive both the stemness and drug resistance of these cells. There are two isoforms of KRAS (KRAS-2A and 2B), and only KRAS-2B was associated with α v β 3 ( Supplementary Fig. 4g ). Interestingly, KRAS-2B is the only RAS isoform containing a polycationic region (poly-lysine) within its hypervariable region 26 , which may be linked to its capacity to associate with α v β 3 in these cells. Together, these findings demonstrate that the ability of α v β 3 to drive tumour stemness and RTK resistance is linked to its capacity to associate with the 2B isoform of KRAS. Supplementary  Fig. 3e . (g) Histological analysis of primary HCC827 erlotinib-resistant xenografts and integrin β 3 + and integrin β 3 − subpopulations. Tumours were stained for haematoxylin and eosin (H&E) and integrin β 3 . Scale bar, 50 µm. (h) Box plot comparing integrin β 3 (ITGβ 3 ) gene expression in human lung cancer biopsies from patients from the BATTLE Study 24 who were previously treated with an EGFR tyrosine kinase inhibitor (TKI) and progressed (n = 31 patients), versus patients who were EGFR TKI naive (n = 43 patients). The box plot shows the median and the interquartile range, and the whiskers show the sample minimum and the sample maximum. (i) Immunohistochemical analysis of integrin β 3 expression in paired human primary lung cancer biopsies obtained from three separate patients before and after erlotinib resistance. Scale bar, 100 µm. The P-value was estimated by Student's t-test in b,c,d,e,h; χ 2 test in f. *P < 0.05, **P < 0.01, ***P < 0.001. Original data for d,e are provided in the statistical source data (Supplementary Table 3) . by CellTiter-Glo cell viability assay for FGβ 3 , PANC-1 and A549. Cells were grown in 3D in medium containing 10% or 0% serum. The bar graph represents the mean ± s.d. for n = 3 independent experiments. (g) Selfrenewal capacity of FGβ 3 cells expressing non-target shRNA control or KRAS-specific shRNA measured by quantifying the number of primary and secondary tumour spheres. The bar graph represents the mean for three wells per group. Data are representative of two independent experiments. Phase contrast microscopy images of self-renewal tumour spheres of FGβ 3 cells expressing non-silencing shRNA CTRL or specific KRAS shRNA. Scale bar, 100 µm. The P-value was estimated using Student's t-test in b,d-f. *P < 0.05, **P < 0.01, ***P < 0.001. Uncropped western blots are provided in Supplementary Fig. 7 and original data for b,d-g are provided in the statistical source data (Supplementary Table 3 ). Phase contrast microscopy images of self-renewal tumour spheres of PANC-1 cells expressing non-silencing shRNA control or galectin-3-specific shRNA. Scale bar, 100 µm. The P-value was estimated by Student's t-test in c,d. *P < 0.05, **P < 0.01, ***P < 0.001. Uncropped western blots are provided in Supplementary Fig. 7 and original data for c-e are provided in the statistical source data (Supplementary Table 3 ).
There are no obvious KRAS binding sites on the β 3 cytoplasmic tail, making it possible that the KRAS-β 3 interaction occurs through an intermediary. In fact, galectin-3, linked to tumour progression 27 , has been reported in separate studies to interact with KRAS (ref. 28) or integrin α v β 3 (ref. 29) . Therefore, we considered if galectin-3 might serve as an adaptor facilitating the β 3 -KRAS interaction that could be linked to tumour stemness and RTK resistance. Indeed, knockdown of galectin-3 in β 3 + PANC-1 cells not only prevented the formation of this KRAS-β 3 complex (Fig. 5a,b) but also reversed the anchorage independence, erlotinib resistance and self-renewal induced by α v β 3 (Fig. 5c-e and Supplementary Fig. 4h ). Together, these findings provide evidence that galectin-3 facilitates a specific interaction between α v β 3 and KRAS that seems to be required for the induction of stem-like properties and erlotinib resistance of epithelial cancers.
RalB is a key modulator of integrin-β 3 -mediated tumour-initiating phenotype and EGFR inhibitor resistance The activation of KRAS elicits changes in cellular function by signalling through a number of downstream effectors, most prominently AKT-PI3K, RAF-MEK-ERK and Ral GTPases 30 . Depletion of Akt, Erk or RalA produced an equivalent inhibition of 3D growth among β 3 + and β 3 − tumour cells (Supplementary Fig. 5a ), suggesting that these effectors were not specifically involved in the ability of α v β 3 to enhance stemness. In contrast, knockdown of RalB not only selectively impaired 3D colony formation of β 3 + cells (Fig. 6a and Supplementary Fig. 5b ), but also reversed β 3 -mediated stemness (Fig. 6b,c and Supplementary Fig. 5b,c) and resistance to nutrient deprivation or erlotinib treatment (Fig. 6d-g and Supplementary  Fig. 5d ). Importantly, in FG pancreatic tumour cells expressing test in c. *P < 0.05, **P < 0.01, ***P < 0.001. Uncropped western blots are provided in Supplementary Fig. 7 and original data for a,b,d-f are provided in the statistical source data (Supplementary Table 3 ). α v β 3 we observed RalB activation in a manner that depended on KRAS co-expression (Fig. 6h) . Clinically, we could detect colocalization between α v β 3 and RalB in biopsies from pancreatic cancer patients (Fig. 6i) . In fact, the activation of RalB was sufficient for erlotinib resistance, because expression of a constitutively active RalB G23V mutant in β 3 − tumour cells conferred erlotinib resistance (Supplementary Fig. 5e) .
Consistent with recent studies that have linked RalB and its effectors, TBK1 and NF-κB, to RTK inhibitor resistance, cell survival and stemness [31] [32] [33] , β 3 + tumour cells showed enhanced activation of these effectors relative to that of their β 3 − tumour cell counterparts. RalB knockdown restored the ability of erlotinib to inhibit NF-κB (cRel) in β 3 + tumour cells (Fig. 6j) . Interestingly, this α v β 3 -mediated signalling pathway seemed to be independent of integrin ligation as well as focal adhesion kinase activation, an event that is typically associated with canonical integrin signalling (Fig. 6j ).
TBK1 and c-Rel inhibition overcome β 3 -mediated stemness and EGFR inhibitor resistance
Given this and the fact that RAS and Ral inhibitors have not proven effective clinically, we postulated that interrupting signalling at or downstream of RalB could reverse the stemness and drug resistance of β 3 + tumour cells. Indeed, genetic inhibition of TBK1 or c-Rel overcame β 3 -mediated self-renewal and erlotinib and nutrient deprivation resistance (Fig. 7a-d and Supplementary Fig. 6a-c) . In fact, the proteasome inhibitor bortezomib (clinically approved for myeloma), known to disrupt the NF-κB pathway, when combined with erlotinib overcame β 3 -mediated intrinsic or acquired erlotinib resistance in vitro and in vivo (Fig. 7e-h and Supplementary  Fig. 6d,e) . Importantly tumours treated with a combination of erlotinib and bortezomib showed a complete loss of the β 3 + stem population (Fig. 7i) .
Proposed model depicting the role of α v β 3 in carcinoma stemness and drug resistance
We have identified integrin α v β 3 as a marker of breast, pancreatic and lung carcinomas that are resistant to RTK inhibitors such as erlotinib or lapatinib. A model of how α v β 3 drives carcinoma stemness and drug resistance is depicted in Fig. 8a . Integrin α v β 3 in the unliganded state, together with galectin-3, recruits KRAS into a membrane complex leading to the hyperactivation of RalB. This complex then leads to TBK1 and NF-κB activation as previously described 34 . We demonstrate that drugs such as bortezomib that target this pathway are able to reverse RTK inhibitor resistance and tumour stemness (Fig. 8b) . Interestingly, targeting the ligand-binding properties of α v β 3 do not influence this pathway, as it is only assembled when α v β 3 is in the unliganded state.
DISCUSSION
Tumour-initiating cells show stem-like properties and are associated with tumour progression, metastasis and drug resistance 11, 35 . Whereas a number of markers, such as CD166, CD133 or CD44, have been identified as cancer stem cell markers for particular cancer types, these are not consistently expressed between different tumour types and their cell surface expression does not necessarily correspond to their overall DNA/RNA/protein expression levels 36 . In fact, their contribution to a stem cell phenotype is unclear. For example, breast cancer TICs are characterized by low levels of CD24 (ref. 37) , whereas high CD24 expression is linked to tumour initiation in pancreatic 38 and lung 39 cancers. Although aldehyde dehydrogenase (ALDH1) is a cytoplasmic enzyme that is expressed in cancer stem cells in leukaemia, breast, lung, colon and prostate cancer 36 , knockdown studies suggest a tumour-suppressive role for this enzyme 40 . Here, we identify CD61 (integrin β 3 ) to be both necessary and sufficient to promote tumour stem properties, including tumour initiation, self-renewal and resistance to RTK inhibition. Importantly, we have observed this function of integrin β 3 for a range of histologically distinct epithelial tumours, including lung, breast and pancreatic carcinomas.
The role of integrin α v β 3 as a cancer stem cell driver is consistent with previous reports linking α v β 3 expression to tumour progression and metastasis for a wide range of cancers 13, 41 , because stemness properties would contribute to these endpoints by promoting drug resistance, tumour growth and ability to invade foreign microenvironments. In normal tissues, integrin α v β 3 becomes expressed on a variety of cell types undergoing tissue remodelling. It specifically contributes to invasion, survival and/or proliferation of luminal progenitor cells in the developing mammary gland 42 , hematopoietic stem cells 43 , endothelial cells undergoing angiogenesis 44 and smooth muscle cells during vascular remodelling 45 . Therefore, the role of integrin α v β 3 that we have uncovered in cancer stem cells may be reminiscent of a more fundamental role for this integrin during development and tissue remodelling during repair. It is important to point out that blocking the ligand-binding function of α v β 3 using cyclic peptides such as cilengitide does not impact the ability of this integrin to promote erlotinib resistance ( Supplementary Fig. 2f ), as we have attributed this behaviour to stem-like abilities including anchorage-independent growth that would not be impacted by disrupting cell adhesion. In fact, expression of a ligand-binding-defective mutant of α v β 3 is still able to markedly enhance tumour cell anchorage-independent growth and drug resistance.
Integrin α v β 3 functions as part of a complex with KRAS, and tumours expressing integrin β 3 require KRAS both for their resistance to RTK inhibitors and for self-renewal (Fig. 4d,e) . Our collective results suggest that this β 3 -KRAS interaction may be the crucial event required to drive β 3 -mediated stemness. Formation of this molecular complex seems to be facilitated by galectin-3, a lectin family protein previously reported to bind to β 3 (ref. 29) and KRAS (ref. 28) , separately. We propose that the β 3 -galectin-3-KRAS complex drives stemness and erlotinib resistance by aggregating α v β 3 -KRAS into clusters at the plasma membrane to facilitate the recruitment and hyperactivation of RalB, which is known to drive NF-κB (c-Rel) through TBK1 (refs 32,34) . Galectin-3 is a requirement for α v β 3 -KRAS clustering, and thus knockdown of galectin-3 negates the contribution of α v β 3 to stemness and drug resistance (Fig. 5c-e) . This highlights the potential of targeting galectin-3 as a means to disrupt this pathway in tumours.
Given that β 3 is both necessary and sufficient to account for stemness and drug resistance, it should be possible to target and inhibit β 3 transcription or selectively kill β 3 -expressing tumour cells as a means to prevent or reverse this phenotype. However, preventing β 3 expression will require a better understanding of how this gene Table 3 ). Alternatively, antibody conjugate therapy is gaining popularity as a means to direct a cytotoxic agent such as a toxin, radionuclide, small molecule or enzyme towards a specific cell surface target expressed on tumour cells 52 . Targeting tumour cells using an antibody specific for α v β 3 (refs 53,54) may be particularly advantageous, because its expression in the adult is low except in remodelling or angiogenic tissues 44 , and yet is enriched on the population of drug-resistant, stemlike metastatic tumour cells likely to be present in the circulation.
As shown here, reversing β 3 -mediated drug resistance and stemness was achieved by disrupting its downstream signalling pathway. Perhaps the most straightforward approach to disable β 3 -mediated stemness may be through NF-κB, because previous studies have established NF-κB as a transcription factor for a range of genes associated with tumour epithelial-to-mesenchymal transition and drug resistance 31, 55 . We reasoned that inhibitors targeting the NF-κB pathway, such as bortezomib 56 , might be combined with RTK inhibition to reverse integrin-β 3 -mediated drug resistance. Not only did bortezomib sensitize α v β 3 -expressing tumours to erlotinib, but combining these agents prevented acquired resistance to erlotinib (Fig. 7h) and eradicated the stem-like cells within the tumour. Repurposing bortezomib, an already FDA-approved therapy for multiple myeloma, could represent a promising and feasible strategy to sensitize lung and pancreas carcinomas to the effects of erlotinib.
Here, we define a non-canonical function for α v β 3 as a marker and driver of cancer stemness and drug resistance. Once expressed on the carcinoma cell surface, α v β 3 couples to galectin-3 and KRAS, promoting the recruitment and activation of RalB, leading to the induction of TBK1 and NF-κB activity. Targeting of this pathway genetically or pharmacologically was able to reverse cancer stemness and drug resistance (Fig. 8 ). These findings demonstrate how the expression of a single integrin can reprogram tumour cells towards a stem-like state that enhances tumour progression and therapy resistance.
METHODS
Methods and any associated references are available in the online version of the paper. (UCSD). BT20 cells were a gift from J. Yeng (UCSD). H441, H23, HCC827 and H1650 are from ATCC. We obtained FGβ 3 , FG D119A mutant and PANC shβ 3 cells as previously described 13 . All cell lines were confirmed to be mycoplasma negative before experiments. Erlotinib, linsitinib, gemcitabine, bortezomib and lapatinib were purchased from ChemieTek. Cisplatin was purchased from Sigma-Aldrich. Cilengitide was made in D.A.C. 's laboratory or purchased from Creative Peptide.
Patient-derived xenograft implantation. The pancreatic PDXs were provided by A.L. at UCSD. This research was approved by UCSD Institutional Review Board (IRB) protocol 090401. All participants provided written informed consent. Samples were washed with cold PBS with antibiotics three times, chopped with a sterile blade and incubated in 0.001% DNase (Sigma-Aldrich), 1 mg ml −1 collagenase/dispase (Roche), 200 U ml −1 penicillin and 200 mg ml −1 streptomycin in DMEM/F12 medium in a 37 • C water bath for 1 h with intermittent shaking. After incubation, the suspensions were repeatedly triturated, passed through 70 mm and 40 mm cell strainers and centrifuged at 300 g for 5 min at 4 • C. Cells were re-suspended in red blood cell lysis buffer for 4 min at room temperature with intermittent shaking, before re-suspension in serum-free medium. Table 1 ).
In vivo experiments. All research was conducted under protocol S05018 and approved by the UCSD Institutional Animal Care and Use Committee. The number of mice used for each experiment is indicated in relevant figures.
Limiting dilution. NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) female mice (Jackson Laboratories) at six to eight weeks old were subcutaneously transplanted with single-cell suspensions from lung and pancreas PDXs in Matrigel Basement Membrane Matrix Phenol Red-Free (BD Biosciences) and PBS 1:1. After 40 days palpable tumours were counted, and the TIC frequency was calculated using the ELDA software.
10, 10 2 , 10 3 , 10 4 , 10 5 and 10 6 A549 shCTRL, A549 shβ 3 , FG, Fβ 3 and FGβ 3 shCTRL, FGβ 3 shRalB, HCC827 vehicle-treated, HCC827 erlotinib-treated and HCC827 erlotinib-treated β 3 + population and HCC827 erlotinib-treated β 3 − population cells were suspended in a mixture of Basement Membrane Matrix Phenol Red-Free (BD Biosciences) and PBS 1:1 and injected into the flanks of six/eightweek-old female immune-compromised nu/nu mice or NSG mice. After 30 days, palpable tumours were counted and the TIC frequency was calculated using the ELDA software. The experiments were not randomized. The investigators were blinded to allocation during outcome assessment. Animals were excluded only if they died before the pre-determined time for killing. No statistical method was used to determine sample size.
Orthotopic pancreas cancer xenograft model. FG pancreatic carcinoma cells (1 × 10 6 tumour cells in 30 µl of PBS) were injected into the pancreas of six-to eight-week-old male nude mice as previously described 13 . Tumours were established for 2-3 weeks (tumour sizes were monitored by ultrasound) before beginning dosing. Mice were dosed by oral gavage with vehicle (6% Captisol) or 10, 25 and 50 mg kg −1 per day erlotinib for 10-30 days before harvest. The experiments were randomized; four randomly chosen animals were monitored by ultrasound to follow the cancer progression. When the tumour size reached 1,000 mm 3 , animals were randomly allocated to experimental groups. The investigators were blinded to allocation during experiments and outcome assessment. To determine whether animals should be exclude from the analysis we used the Gribb's test outlier calculator from GraphPad software (GraphPad.com) with α = 0.05. A statistical method was used to predetermine sample size.
Orthotopic lung cancer xenograft model. Tumours were generated as previously described 57 . Male eight-week-old athymic NCr (nu/nu) mice were injected with tumour cells. Three weeks later, the mice were treated with vehicle or erlotinib (100 mg kg −1 per day) by oral gavage until moribund (approximately 50 and 58 days, respectively). The experiments were randomized; three weeks after implantation eight mice were killed for evaluation of baseline tumour volume (n = 8). Animals were allocated to experimental groups. The investigators were not blinded to allocation during experiments and outcome assessment. Animals were excluded only if they died before the pre-determined time for killing. No statistical method was used to determine sample size.
Flank cancer xenograft model. A549, FGβ 3 and HCC827 human carcinoma cells (5 × 10 6 tumour cells in 200 µl of PBS) were injected subcutaneously into the left or right flank of six-to eight-week-old female nude mice. Tumours were measured every 2-3 days with callipers until they were harvested. Mice were treated with erlotinib 25 mg kg −1 per day (oral gavage) or bortezomib 0.25 mg kg −1 twice a week (intraperitoneal injection). The experiments were randomized; tumour sizes were monitored three times per week until they reached 150/200 mm 3 . Then, animals with a tumour size between 150 and 250 mm 3 were allocated to each group to give identical averages. The investigators were not blinded to allocation during experiments and outcome assessment. To determine whether animals should be exclude from the analysis we used the Gribb's test outlier calculator from GraphPad software (GraphPad.com) with α = 0.05. No statistical method was used to determine sample size.
Establishment of erlotinib-resistant tumours. Human lung cancer HCC827 cells
were injected subcutaneously into the flanks of six-to eight-week-old nude mice (5 × 10 6 tumour cells in 200 µl of PBS). Tumour-bearing mice (tumour size of 500-1,000 mm 3 ) were randomized for treatment with vehicle (Captisol 6%) or erlotinib HCl at 25 mg kg −1 d −1 administered by oral gavage until resistance acquired as already described 58 . The experiments were randomized. The investigators were not blinded to allocation during experiments and outcome assessment. Animals were not excluded. No statistical method was used to determine sample size.
Tumour single-cell isolation for HCC827 ER model. Fresh tumour tissue from lung cancer cell lines was mechanically dissociated and then enzymatically digested in DMEM/F12 medium supplemented with 0.001% DNase, 300 U ml −1 collagenase I and 100 U ml −1 hyaluronidase (Sigma) for 2 h at 37 • C. The tissue was further enzymatically digested with HyQTase (HyClone) and filtered through a cell strainer to obtain a suspension of single tumour cells. Cell viability was evaluated by trypan blue dye exclusion. Cells were then kept in culture for one/two weeks and then FACS sorted into two distinct populations, the integrin β 3 − and the integrin β 3 + populations, with LM609 antibody.
NSCLC specimens from the BATTLE trial. The BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) trial was a randomized phase II, single-centre, open-label study in patients with advanced NSCLC refractory to prior chemotherapy and included patients with and without prior EGFR TKI treatment 24 . Patients underwent a new tumour biopsy before initiating study treatment. The microarray analysis of mRNA expression on frozen tumour core biopsies was conducted using the Affymetrix Human Gene 1.ST platform as previously described. (Trial registration ID: NCT00409968, MD Anderson Cancer Center.) The institutional review boards of MD Anderson Cancer Center and the US Department of Defense approved the study, which was monitored by an independent data and safety monitoring board. All participants provided written informed consent.
Serial biopsies from NSCLC patients. This research was approved by UCSD Institutional Review Board protocol 111755. The study was reviewed through the expedited review procedure as authorized by 45 CFR 46.110 and 21 CFR 56.110 and falls under the following research category: (5) Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected solely for non-research purposes (such as medical treatment or diagnosis). Therefore, it was determined that waiver of informed consent would be granted. Tumour biopsies from UCSD Medical Center stage IV NSCLC patients were obtained before and after erlotinib resistance. All biopsies are from lung or pleural effusion. Patient 1 (EGFR mutant) had a core biopsy from the primary lung tumour, and patients 2 (EGFR wild type) and 3 (EGFR unknown) had a fine needle biopsy from a pleural effusion. All patients had an initial partial response, followed by disease progression after 920, 92 and 120 days of erlotinib therapy, respectively. This work was approved by the UCSD Institutional Review Board. Tumour-sphere culture and self-renewal assay. Single cells were seeded on ultralow attachment plates at a concentration of 1,000 cells ml −1 in DMEM/F12 medium containing insulin-transferrin-selenium (BD Biosciences) and supplemented with 50 ng ml −1 EGF and 20 ng ml −1 bFGF (Invitrogen). Fresh medium was replenished every week. Tumour spheres larger than 50 µm in diameter were counted 14 days after seeding (primary tumour spheres). All the primary spheres were isolated from the rest of the cells, dissociated with HyQTase and filtered through a 40 µm cell strainer to obtain a single-cell suspension. Equal numbers of single cells (1,000 cells ml −1 ) were then seeded on ultralow attachment plates. The number of tumour spheres was counted after 14 days (secondary tumour spheres).
Soft agar assay. Soft agar formation assays were carried out essentially as described previously 13 . Cells were treated with vehicle (dimethylsulphoxide), erlotinib (10 nM-5 µM), lapatinib (10 nM-5 µM), gemcitabine (0.001 nM-5 µM), linsitinib (10 nM-5 µM), cisplatin (10 nM-5 µM), cilengitide (5 µM) or bortezomib (4 and 8 nM) diluted in dimethylsulphoxide. The medium was replaced with fresh inhibitor two/five times a week. Survival curves to calculate IC 50 were generated at least with five concentration points.
Cell viability assay. Cell viability assays were carried out as described 31 . Briefly, cells were seeded at a density of 5,000/10,000 cells per well in low adherent 96-well plates. Then the cells were treated with the relevant agents for 3 days. Viable cell numbers were determined using the CellTiter-Glo assay kit according to the manufacturer's protocols (Promega). Each assay consisted of two or three replicate wells and was repeated at least twice. Data were expressed as relative luciferase units or as percentages of the survival of control cells, calculated from the absorbance corrected for background.
Quantitative PCR with reverse transcription. Total RNA was collected from tumour tissue using an RNeasy RNA Purification kit (Qiagen). cDNA was synthesized with SuperScript III reverse transcriptase using oligo(dT) primers (Invitrogen), and PCR with reverse transcription was carried out on a LightCycler with SYBR Green probes (Roche). Cyclophilin A expression was used as an internal reference to normalize input complementary DNA. Ratios of the expression level of each gene to that of the reference gene were then calculated.
Primer sequences used: ITGB3 forward, 5 -GTGACCTGAAGGAGAATCTGC-3 ; ITGB3 reverse, 5 -TCACTCACTGGGAACTCGATG-3 ; ALDH1 forward, 5 -CCAAAGACATTGATAAAGCCATAA-3 ; ALDH1 reverse, 5 -CACGCCATAG CAATTCACC-3 ; cyclophilin A forward, 5 -ATGCTGGACCCAACACAAAT-3 ; cyclophilin A reverse, 5 -TCTTTCACTTTGCCAAACACC-3 .
The ALDH and cyclophilin A primers were designed using Roche's ProbeFinder program version 2.49.
Immunofluorescence microscopy. Frozen sections from tumours from patients diagnosed with pancreas or tumour cell lines were processed as previously described 59 . Cells were stained with indicated primary, followed by secondary antibodies specific for mouse or rabbit (Invitrogen), as appropriate. Samples were imaged on a Nikon Eclipse C1 confocal microscope with a 1.4 NA ×60 oilimmersion lens, using the minimum pinhole (30 µm). Co-localization between integrin β 3 and KRAS was studied using Zenon Antibody Labeling Kits (Invitrogen) with integrin β 3 (LM609) and KRAS (Abgent) antibodies (Supplementary Table 1 ).
Immunohistochemical analysis.
Immunostaining was carried out according to the manufacturer's recommendations (Vector Labs) on 5 µM sections of paraffinembedded tumours from tumour biopsies from lung cancer patients. Tumour sections were processed as previously described 59 Table 1 ). Sections were stained with integrin β 3 and scored using an H-score according to the staining intensity on a scale of 0-3 within the whole tissue section.
Genetic knockdown and expression of mutant constructs. Cells were transfected with vector control, wild-type, G23V RalB-Flag, or integrin β 3 using a lentiviral system. For knockdown experiments, cells were transfected with RALA, RALB, AKT1, ERK1/2 short interfering RNA (siRNA; Qiagen) using lipofectamine reagent (Invitrogen) following the manufacturer's protocol or transfected with shRNA (Open Biosystems) using a lentiviral system. Gene silencing was confirmed by immunoblot analysis. The siRNA and shRNA used in this study have been described in Supplementary Table 2 .
Immunoprecipitation and immunoblots. Lysates from cell lines and xenograft tumours were generated using radioimmunoprecipitation assay and Triton buffers. Immunoprecipitation experiments were carried out as previously described 1 with anti-KRAS antibody. For immunoblot analysis, 25 µg of protein was boiled in Laemmli buffer and resolved on an 8-15% gel. The antibodies used here are described in Supplementary Table 1 .
Affinity pulldown assays for Ral. Ral activation assays were carried out in accordance with the manufacturer's (Upstate) instruction. Briefly, cells were cultured in suspension for 3 h. 10 µg of Ral Assay Reagent (Ral BP1, agarose) was added to 1 mg of total cell protein in MLB buffer (Millipore). After 30 min of rocking at 4 • C, the activated (guanosine triphosphate) forms of Ral bound to the agarose beads were collected by centrifugation, washed, boiled in Laemmli buffer and loaded on a 15% SDS-polyacrylamide electrophoresis gel.
Statistical analyses.
All statistical analyses were carried out using Prism software (GraphPad). Chi-squared tests, one-way ANOVA tests or t-tests were used to calculate statistical significance. A P-value less than 0.05 was considered to be significant. A statistical method was used to predetermine sample size for the FG model. No statistical method was used to determine sample size for the A549, HCC827 model or for limiting dilution experiments. 
Repeatability of experiments.

